CANbridge Life Sciences
嘉和生物
Executive Summary
CANbridge Life Sciences is a Beijing/Cambridge-based biotech with dual-geography operations that appears clear of BIOSECURE designation. The company maintains a low profile with limited public information on recent corporate activities or leadership changes. Without detailed pipeline or deal history data, BD teams should approach with standard due diligence protocols while benefiting from apparent regulatory clarity.
Structure: CANbridge operates with dual headquarters in Beijing and Cambridge, suggesting a cross-border structure typical of Chinese biotechs seeking global reach. Without detailed subsidiary information, the exact corporate structure remains unclear, requiring standard VIE and ownership verification during due diligence.
BIOSECURE Risk
Company shows clear BIOSECURE status with no BCC designation, indicating lower regulatory risk for US partnerships
Key Exposures:
- •Beijing headquarters location
- •Potential undisclosed Chinese government connections
- •Supply chain dependencies in China
Mitigation: Cambridge presence suggests international diversification strategy, though specific BIOSECURE mitigation measures unknown
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity identified in available data
Approach: Initiate preliminary discussions with standard information requests to assess pipeline depth and partnership readiness
Red Flags
- ⚠Limited public information availability
- ⚠Unclear corporate structure details
- ⚠No recent corporate activity or milestones identified
- ⚠Unknown pipeline status and development stage
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.